Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.

•VWF-containing FVIII products may improve immune tolerance induction success rates.•We analysed the use of BIOSTATE for ITI in 15 paediatric patients with inhibitors.•BIOSTATE was used for primary ITI in 8 patients and for salvage ITI in 7 patients.•Overall response rate was 86.6% with 11 patients achieving a complete response.•BIOSTATE was well-tolerated and effective when used for primary or salvage ITI.